Ainos (AIMD) versus Its Peers Head-To-Head Contrast

Ainos (NASDAQ:AIMD) is one of 1,000 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Ainos to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, profitability and valuation.

Insider & Institutional Ownership

44.7% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 4.6% of Ainos shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ainos and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	-11,205.49%	-47.96%	-40.37%
Ainos Competitors	-2,459.06%	-249.83%	-30.60%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ainos and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0	0	0	0	N/A
Ainos Competitors	6394	18740	44698	917	2.57

As a group, “Pharmaceutical preparations” companies have a potential upside of 84.06%. Given Ainos’ competitors higher possible upside, analysts clearly believe Ainos has less favorable growth aspects than its competitors.

Risk and Volatility

Ainos has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Ainos’ competitors have a beta of 1.09, suggesting that their average stock price is 9% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ainos and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Ainos	$120,000.00	-$13.77 million	-0.41
Ainos Competitors	$1.68 billion	$146.16 million	-1.65

Ainos’ competitors have higher revenue and earnings than Ainos. Ainos is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Ainos competitors beat Ainos on 7 of the 10 factors compared.

Ainos Company Profile

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.